Net loss for the three months ended March 31, 2026, was $2.97 million, compared to $2.12 million in the same period of 2025. Cash and cash equivalents were $5.16 million as of March 31, 2026. The company is winding down its BayMedica commercial operations, expected to be completed by June 30, 2026. Management expects current cash to fund operations into the fourth quarter of calendar 2026. The company received a Nasdaq delisting notice regarding minimum bid price requirements on March 27, 2026.